IceCure Medical Ltd. (Nasdaq: ICCM), a developer of minimally-invasive cryoablation technology for tumor destruction, announced its participation at the European Society of Breast Imaging (EUSOBI) Congress 2025 in Aberdeen, United Kingdom. At the congress, positive results from five independent studies utilizing the company's ProSense® cryoablation system for breast cancer treatment were presented. Highlights included an exclusive, fully attended workshop on cryoablation for breast cancer de-escalation of care. Among the studies presented, Dr. Elisabet Vila Trias reported on the feasibility, safety, and preliminary clinical outcomes of ultrasound-guided percutaneous cryoablation in 16 patients with low-risk early-stage breast cancer, indicating that the procedure may be a viable minimally invasive alternative to surgery. Additionally, Dr. Federica Di Naro and Dr. Sofia Baldi Giorgi presented an investigator-initiated study evaluating the efficacy of percutaneous cryoablation for local control of invasive breast cancer compared to hormone therapy in 101 patients, with tumor response assessed using RECIST 1.1 criteria. The studies indicate ongoing interest in the clinical application and evaluation of cryoablation technology for breast cancer, with calls for further research to confirm long-term oncological effectiveness.